Home page

Synthgene Bio has successively completed A+ rounds of financing of over 300 million yuan, focusing on providing overall solutions for upstream raw materials in the field of life sciences!

Synthgene Bio has successively completed A+ rounds of financing of over 300 million yuan, focusing on providing overall solutions for upstream raw materials in the field of life sciences!

Jiangsu Synthgene Biotechnology Co., Ltd. (hereinafter referred to asSynthgene Bio), the parent company of Nanjing Synthgene Medical Technology Co., Ltd., recently announced the completion of the A+ round of financing. This round of financing was jointly led by Qingchi Capital and LYFE Capital (Zhouling Capital). There are shareholders Sherpa Investment and Lenovo Star continue to make additional investments. Previously, the A1 round was jointly invested by Ruihua Capital, Sherpa Investment, and Legend Star. The two rounds of financing have accumulated a total of over 300 million yuan, and Life Capital served as the exclusive financial advisor for this financing.

11

2022

/

04

Statement丨 Synthgene's SARS-CoV-2 Antigen Rapid Detection Kit is effective!

Statement丨 Synthgene's SARS-CoV-2 Antigen Rapid Detection Kit is effective!

It has been verified that Synthgene's SARS-CoV-2 antigen kit is effective for the reported new coronavirus mutants!

10

2022

/

04

Synthgene News丨Jiangsu Provincial Food and Drug Administration Director Tian Feng investigates Synthgene

Synthgene News丨Jiangsu Provincial Food and Drug Administration Director Tian Feng investigates Synthgene

On the second day after the approval of Synthgene's SARS-CoV-2 antigen reagent, Director Tian Feng of the Provincial Food and Drug Administration led a team to Synthgene. for investigation. Chang Tongkun and others accompanied them to participate in the investigation.

04

2022

/

04

Synthgene Medical| Home self-test OTC hot hits are coming!

Synthgene Medical| Home self-test OTC hot hits are coming!

On April 1, 2022, SARS-CoV-2 (2019-nCoV) antigen detection kit (colloidal gold) developed by Nanjing Synthgene Technology Co., Ltd. (“ Synthgene”), a wholly-owned subsidiary of Jiangsu Synthgene Biotechnology Co., Ltd. Law) obtained the "Medical Device Registration Certificate" issued by the National Medical Products Administration (NMPA).

04

2022

/

04

Blockbuster丨SARS-CoV-2's antigen detection reagent was successfully approved in China!

Blockbuster丨SARS-CoV-2's antigen detection reagent was successfully approved in China!

On April 1, 2022, the novel coronavirus (2019-nCoV) antigen detection kit (colloidal gold method) developed by Nanjing Synthgene Medical Technology Co., Ltd. was approved by the State Food and Drug Administration (Registration Certificate No.: National Machinery Note 20223400427) and officially launched. Contribute to the rapid screening of the SARS-CoV-2 and the fight against the SARS-CoV-2 epidemic!

01

2022

/

04

< 1...4 5 6...8 >

Nanjing Synthgene Medical Technology Co., Ltd.

Nanjing Synthgene Medical Technology Co., Ltd. is a biomedical high-tech enterprise focusing on the development and production of OTC home self-inspection products. The company has a mature technology platform, including chromatography platform, isothermal amplification platform, etc.

Messages

Messages

whatsapp

whatsapp

Tel

+86 17721538411

E-mail

E-mail

TOP

Contact Us

Address：Building B6-2, No. 9, Weidi Road, Xianlin University Town, Xianlin Subdistrict, Qixia District, Nanjing City, China
Tel: +86 17721538411

Email: info@syngenebio.com

After-sale Email ： service@syngenebio.com

Copyright © Nanjing Synthgene Medical Technology Co., Ltd. | SEO | Powered by： www.300.cn

Business License

Close

Inquiry

Total X Clear all